13 completed, 5 recruiting, 1 not yet recruiting, 1 terminated. 8 Phase 3, 5 Phase 1, 3 Phase 2, 1 Phase 4.
By phase and status
Follow maribavir: new trials by email Literature Review of maribavir trials Research Report on maribavir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCT Maribavir - Hematologic Malignancy Phase 3 Recruiting 218 2026-02-28 2026-04-06 Phase II Trial of Maribavir for CMV in Patients With Lymphoid Malignancy on Bispecific Antibodies Maribavir - Cytomegalovirus (CMV) Phase 2 Recruiting 20 2025-11-03 2025-12-04 A Prospective Single-Arm Observational Study of Maribavir for the Treatment of Post Hematopoietic Stem Cell Transplantation Cytomegalovirus Infection maribavir - Infections, Cytomegalovirus Not yet recruiting 17 2025-09-25 2025-08-26 A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections Maribavir - Cytomegalovirus (CMV) Phase 3 Completed 20 2024-12-16 2026-09-24 A Study of LIVTENCITY (Maribavir) in Adults With Cytomegalovirus (CMV) Infection After Transplantation in South Korea LIVTENCITY - Cytomegalovirus (CMV) Recruiting 168 2024-11-14 2026-11-06 A Survey of Maribavir Tablets in Participants With Cytomegalovirus Infection Maribavir - Cytomegalovirus (CMV) Recruiting 250 2024-08-28 2026-08-07 A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT) Maribavir - Cytomegalovirus (CMV) Phase 3 Recruiting 80 2023-11-13 2026-05-22 Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients Maribavir, Valganciclovir - Transplant Complication, CMV Phase 4 Completed 70 2023-11-06 2026-04-30 Maribavir Food-Effect Study in Healthy Adults Participants Maribavir - Healthy Volunteers Phase 1 Completed 31 2022-05-25 2024-02-16 A Study of Maribavir in Japanese People With Cytomegalovirus (CMV) Infection Maribavir - Cytomegalovirus (CMV) Phase 3 Completed 41 2022-01-18 2024-07-09 A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Maribavir Administered in Healthy Japanese Participants Compared With Matched, Healthy, Non-Hispanic, Caucasian Participants and to Assess Dose-Proportionality of 3 Doses of Maribavir in Japanese Participants Maribavir (400 mg), Maribavir (200 mg), Maribavir (800 mg) - Healthy Volunteers Phase 1 Completed 24 2020-08-07 2025-09-11 A Study Comparing the Pharmacokinetics and Palatability of Two Candidate Pediatric Powder-for-Oral-Suspension Formulations of Maribavir to the Current Maribavir Tablet Formulation Administered in Healthy Adult Participants Maribavir - Healthy Volunteers Phase 1 Terminated 20 2019-10-25 2025-09-02 A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants Maribavir, Valganciclovir, Placebo - Cytomegalovirus (CMV) Phase 3 Completed 553 2017-04-14 2023-03-03 Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir Maribavir, Ganciclovir, Valganciclovir - Cytomegalovirus (CMV) Phase 3 Completed 352 2016-12-22 2021-11-03 Study of SHP620 (Maribavir) in Healthy Adults Digoxin, Maribavir, Dextromethorphan - Cytomegalovirus (CMV) Phase 1 Completed 18 2016-07-21 2021-06-03 Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients Maribavir - Cytomegalovirus (CMV) Phase 2 Completed 120 2012-07-17 2021-06-02 Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients maribavir, ganciclovir - Cytomegalovirus Infections Phase 3 Completed 307 2007-07-23 2021-06-11 Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients maribavir, placebo - Cytomegalovirus Infections Phase 3 Completed 681 2006-12-13 2021-06-11 Maribavir for Prevention of CMV After Stem Cell Transplants Maribavir, Placebo - Cytomegalovirus Infection Phase 2 Completed 111 2004-10-28 2021-05-13 The Safety and Effectiveness of Different Dose Levels of 1263W94 in the Treatment of Cytomegalovirus (CMV) of the Eyes in HIV-Infected Patients Maribavir - Cytomegalovirus Infections, HIV Infections Phase 1 Completed 56 2005-06-24
Conditions studied Cytomegalovirus Infections (5) · Acquired Immunodeficiency Syndrome (1) · HIV Infections (1) · Hematologic Neoplasms (1) · Lymphoma (1)
Sponsors Shire (9) · Takeda (6) · Glaxo Wellcome (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Medical University of South Carolina (1) · Ruijin Hospital (1) · Seoul National University Hospital (1)
Countries United States (13) · China (5) · Belgium (4) · France (4) · Germany (4) · Spain (4) · United Kingdom (4) · Australia (3) · Canada (3) · Italy (3) · Japan (3) · South Korea (3) · Austria (2) · Croatia (2) · Israel (2)
Results publications PMID 38071422 , PMID 38700045 , PMID 18285548 , PMID 21414843 , PMID 23870704 , PMID 30329038 , PMID 31385617 , PMID 32726419 , PMID 33811823 , PMID 34864943 , PMID 37506264 , PMID 37899366 , PMID 38036487 , PMID 38447094 , PMID 38708555 , PMID 39302855 , PMID 39613120 , PMID 39807668 , PMID 40478680 , PMID 41018408 , PMID 41121745 , PMID 41384277 , PMID 42283791
NIH funding 2015 (2) , 2023 (1)